Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 January 2014Website:
http://www.glycomimetics.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:59:57 GMTDividend
Analysts recommendations
Institutional Ownership
GLYC Latest News
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML). The event will feature the study'.
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer Edwin Rock - Chief Medical Officer Brian Hahn - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - TD Cowen Operator Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode.
GlycoMimetics' Phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until early 2024, with the FDA seeking more information on survivability rates. Insider buying and technical momentum indicators suggest a bullish outlook for the company's stock, currently trading at $1.85 per share. The drug has the potential to be used in combination therapies for various cancer treatments, but investors should consider the risks and only allocate a small portion of their portfolio to GlycoMimetics.
Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood cancers such as AML, MM, and MDS extract a terrible toll on patients and their loved ones.
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q4 2022 Results Conference Call March 29, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel and Company Secretary Harout Semerjian - Chief Executive Officer Brian Hahn - Chief Financial Officer Edwin Rock - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Operator Good morning. And thank you for joining the GlycoMimetics Fourth Quarter and Full Year 2022 Earnings Call.
What type of business is GlycoMimetics?
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
What sector is GlycoMimetics in?
GlycoMimetics is in the Healthcare sector
What industry is GlycoMimetics in?
GlycoMimetics is in the Biotechnology industry
What country is GlycoMimetics from?
GlycoMimetics is headquartered in United States
When did GlycoMimetics go public?
GlycoMimetics initial public offering (IPO) was on 10 January 2014
What is GlycoMimetics website?
https://www.glycomimetics.com
Is GlycoMimetics in the S&P 500?
No, GlycoMimetics is not included in the S&P 500 index
Is GlycoMimetics in the NASDAQ 100?
No, GlycoMimetics is not included in the NASDAQ 100 index
Is GlycoMimetics in the Dow Jones?
No, GlycoMimetics is not included in the Dow Jones index
When does GlycoMimetics report earnings?
The next expected earnings date for GlycoMimetics is 02 August 2024